Cited by 240Neurological Disease Mechanisms and TreatmentsDementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

The Science of Vascular Contributions to Cognitive Impairment and Dementia (VCID): A Framework for Advancing Research Priorities in the Cerebrovascular Biology of Cognitive Decline

Open access
Corriveau, Roderick A., Bosetti, Francesca, Emr, Marian, Gladman, Jordan T., Koenig, James I., Moy, Claudia S., Pahigiannis, Katherine, Waddy, Salina P. +1 more·2016·Cellular and Molecular Neurobiology

Abstract

The World Health Organization reports that 47.5 million people are affected by dementia worldwide. With aging populations and 7.7 million new cases each year, the burden of illness due to dementia approaches crisis proportions. Despite significant advances in our understanding of the biology of Alzheimer's disease (AD), the leading dementia diagnosis, the actual causes of dementia in affected individuals are unknown except for rare fully penetrant genetic forms. Evidence from epidemiology and pathology studies indicates that damage to the vascular system is associated with an increased risk of many types of dementia. Both Alzheimer's pathology and cerebrovascular disease increase with age. How AD affects small blood vessel function and how vascular dysfunction contributes to the molecular pathology of Alzheimer's are areas of intense research. The science of vascular contributions to cognitive impairment and dementia (VCID) integrates diverse aspects of biology and incorporates the roles of multiple cell types that support the function of neural tissue. Because of the proven ability to prevent and treat cardiovascular disease and hypertension with population benefits for heart and stroke outcomes, it is proposed that understanding and targeting the biological mechanisms of VCID can have a similarly positive impact on public health.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s10571-016-0334-7

Cites

73 of 73 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • A framework for research priorities in the cerebrovascular biology of cognitive decline has been proposed, including development and validation of imaging and biospecimen-based biomarkers, better experimental models, and increased understanding of molecular and physiological mechanisms and vascular-Alzheimer interactions.

    “A framework for research priorities in the cerebrovascular biology of cognitive decline has been proposed 164 . The priorities include the development and validation of imaging and biospecimen‐based biomarkers, better experimental models, and increased understanding of the underlying molecular and physiological mechanisms – white matter disease, infarction, microhemorrhage, vascular autoregulation”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 74 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Corriveau, R. A., Bosetti, F., Emr, M., Gladman, J. T., Koenig, J. I., Moy, C. S., Pahigiannis, K., Waddy, S. P., & Koroshetz, W.
Affiliations
National Institutes of Health (US)
Corresponding author
Corriveau, Roderick A.
Venue
Cellular and Molecular Neurobiology
Published
2016-03
Volume
36
Issue
2
Pages
281-288
ISSN
  • 0272-4340 (ISSN-L)
  • 1573-6830
OpenAlex
W2340837185
Cited by
240
References
74
Citations by year
2026: 22 · 2025: 32 · 2024: 29 · 2023: 22 · 2022: 30 · 2021: 20 · 2020: 22 · 2019: 21 · 2018: 14 · 2017: 16 · 2016: 12
FWCI
1.83
Type
journal article
Language
en
Open access
Locations
  • Cellular and Molecular Neurobiology (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Institutes of Health (Z99 NS999999)
Topics
  • Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
Keywords
cerebrovascular disease, Alzheimer's disease, cognitive decline, vascular dysfunction, dementia risk factors, research priorities, vascular biology, dementia prevention
MeSH terms
Animals, Humans, Models, Biological, Research, Dementia, Vascular, Cost of Illness, Cognitive Dysfunction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review